Advisors Asset Management Inc. Sells 23,197 Shares of Solventum Corporation $SOLV

Key Points

• Advisors Asset Management Inc. reduced its holdings in Solventum Corporation by 50.6%, selling 23,197 shares and holding 22,641 shares valued at approximately $1.72 million as of its latest SEC filing.
• Solventum reported a Q2 earnings of $1.69 per share, surpassing expectations of $1.45 and achieving revenues of $2.16 billion for the quarter, marking a 3.8% increase from the previous year.
• Multiple analysts have upgraded Solventum's stock rating, with price targets rising; Morgan Stanley upgraded its target from $80 to $103, reflecting growing confidence in the company's performance.

Advisors Asset Management Inc. trimmed its holdings in shares of Solventum Corporation (NYSE:SOLV - Free Report) by 50.6% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,641 shares of the company's stock after selling 23,197 shares during the quarter. Advisors Asset Management Inc.'s holdings in Solventum were worth $1,722,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Trian Fund Management L.P. increased its stake in Solventum by 18.8% in the fourth quarter. Trian Fund Management L.P. now owns 8,462,819 shares of the company's stock valued at $559,054,000 after acquiring an additional 1,336,564 shares during the last quarter. Independent Franchise Partners LLP boosted its holdings in shares of Solventum by 263.1% during the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company's stock worth $442,608,000 after purchasing an additional 4,217,570 shares during the period. Davis Selected Advisers boosted its holdings in shares of Solventum by 0.8% during the first quarter. Davis Selected Advisers now owns 5,288,138 shares of the company's stock worth $402,110,000 after purchasing an additional 41,524 shares during the period. Boston Partners boosted its holdings in shares of Solventum by 101.3% during the first quarter. Boston Partners now owns 3,361,973 shares of the company's stock worth $255,554,000 after purchasing an additional 1,691,565 shares during the period. Finally, Northern Trust Corp boosted its holdings in shares of Solventum by 3.3% during the first quarter. Northern Trust Corp now owns 1,807,674 shares of the company's stock worth $137,456,000 after purchasing an additional 58,373 shares during the period.

Solventum Trading Up 0.4%

Shares of SOLV stock opened at $72.70 on Monday. The firm's 50 day moving average is $73.53 and its 200 day moving average is $72.75. The stock has a market capitalization of $12.61 billion, a P/E ratio of 33.66, a P/E/G ratio of 2.97 and a beta of 0.53. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92. The company has a current ratio of 1.22, a quick ratio of 0.86 and a debt-to-equity ratio of 2.14.

Solventum (NYSE:SOLV - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $1.69 earnings per share for the quarter, topping the consensus estimate of $1.45 by $0.24. The business had revenue of $2.16 billion for the quarter, compared to analysts' expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The company's revenue was up 3.8% compared to the same quarter last year. During the same quarter last year, the company posted $1.56 EPS. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. Research analysts expect that Solventum Corporation will post 6.58 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have commented on SOLV. Wall Street Zen upgraded shares of Solventum from a "buy" rating to a "strong-buy" rating in a report on Monday, September 1st. Morgan Stanley upgraded shares of Solventum from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $80.00 to $103.00 in a report on Tuesday, July 15th. KeyCorp began coverage on shares of Solventum in a report on Friday, June 6th. They issued a "sector weight" rating for the company. Wells Fargo & Company raised their price objective on shares of Solventum from $75.00 to $79.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Finally, Piper Sandler restated an "overweight" rating and issued a $94.00 price objective (up from $87.00) on shares of Solventum in a report on Friday, August 8th. Four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $85.75.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.